JAK Inhibition With Ruxolitinib Versus Best Available Therapy for Myelofibrosis

New England Journal of Medicine - United States
doi 10.1056/nejmoa1110556
Full Text
Abstract

Available in full text

Categories
Medicine
Date
Authors
Publisher

Massachusetts Medical Society

Related search

Cost-Effectiveness of Ruxolitinib vs Best Available Therapy in the Treatment of Myelofibrosis in Spain

Journal of Health Economics and Outcomes Research
2017English

Primary Myelofibrosis Associated Glomerulopathy: Significant Improvement After Therapy With Ruxolitinib

BMC Nephrology
Nephrology
2015English

Efficacy of Ruxolitinib for Myelofibrosis

Expert Opinion on Pharmacotherapy
MedicinePharmacology
2014English

Ruxolitinib for Myelofibrosis–An Update of Its Clinical Effects

Clinical Lymphoma, Myeloma and Leukemia
Cancer ResearchOncologyHematology
2013English

Ruxolitinib as an Emerging Treatment in Myelofibrosis

Blood and Lymphatic Cancer: Targets and Therapy
2013English

Placebo Versus Best-Available-Therapy Control Group in Clinical Trials for Pharmacologic Therapies: Which Is Better?

Proceedings of the American Thoracic Society
2007English

Sweet Syndrome Successfully Treated With Ruxolitinib in JAK-2 Positive Myeloproliferative Disorder

2018English

Safety and Efficacy of Ruxolitinib in Myelofibrosis Patients Without Splenomegaly

British Journal of Haematology
Hematology
2015English

Definition and Management of Ruxolitinib Treatment Failure in Myelofibrosis

Blood Cancer Journal
OncologyHematology
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy